BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25730874)

  • 1. Mutant IDH is sufficient to initiate enchondromatosis in mice.
    Hirata M; Sasaki M; Cairns RA; Inoue S; Puviindran V; Li WY; Snow BE; Jones LD; Wei Q; Sato S; Tang YJ; Nadesan P; Rockel J; Whetstone H; Poon R; Weng A; Gross S; Straley K; Gliser C; Xu Y; Wunder J; Mak TW; Alman BA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2829-34. PubMed ID: 25730874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.
    Saiji E; Pause FG; Lascombes P; Cerato Biderbost C; Marq NL; Berczy M; Merlini L; Rougemont AL
    Virchows Arch; 2019 Nov; 475(5):625-636. PubMed ID: 31240473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.
    Jin Y; Elalaf H; Watanabe M; Tamaki S; Hineno S; Matsunaga K; Woltjen K; Kobayashi Y; Nagata S; Ikeya M; Kato T; Okamoto T; Matsuda S; Toguchida J
    PLoS One; 2015; 10(7):e0131998. PubMed ID: 26161668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
    Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
    J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mutant PTH/PTHrP type I receptor in enchondromatosis.
    Hopyan S; Gokgoz N; Poon R; Gensure RC; Yu C; Cole WG; Bell RS; Jüppner H; Andrulis IL; Wunder JS; Alman BA
    Nat Genet; 2002 Mar; 30(3):306-10. PubMed ID: 11850620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
    Grassian AR; Lin F; Barrett R; Liu Y; Jiang W; Korpal M; Astley H; Gitterman D; Henley T; Howes R; Levell J; Korn JM; Pagliarini R
    J Biol Chem; 2012 Dec; 287(50):42180-94. PubMed ID: 23038259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
    Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
    Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
    Zhang H; Puviindran V; Nadesan P; Ding X; Shen L; Tang YJ; Tsushima H; Yahara Y; Ban GI; Zhang GF; Karner CM; Alman BA
    J Bone Miner Res; 2022 May; 37(5):983-996. PubMed ID: 35220602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
    Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
    Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.
    Pansuriya TC; van Eijk R; d'Adamo P; van Ruler MA; Kuijjer ML; Oosting J; Cleton-Jansen AM; van Oosterwijk JG; Verbeke SL; Meijer D; van Wezel T; Nord KH; Sangiorgi L; Toker B; Liegl-Atzwanger B; San-Julian M; Sciot R; Limaye N; Kindblom LG; Daugaard S; Godfraind C; Boon LM; Vikkula M; Kurek KC; Szuhai K; French PJ; Bovée JV
    Nat Genet; 2011 Nov; 43(12):1256-61. PubMed ID: 22057234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
    Akiyama M; Yamaoka M; Mikami-Terao Y; Ohyama W; Yokoi K; Arakawa Y; Takita J; Suzuki H; Yamada H
    Int J Hematol; 2015 Dec; 102(6):723-8. PubMed ID: 26508204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
    Reitman ZJ; Sinenko SA; Spana EP; Yan H
    Blood; 2015 Jan; 125(2):336-45. PubMed ID: 25398939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 R132C and ERC2 L309I Mutations Contribute to the Development of Maffucci's Syndrome.
    Cheng P; Chen K; Zhang S; Mu KT; Liang S; Zhang Y
    Front Endocrinol (Lausanne); 2021; 12():763349. PubMed ID: 34790172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.
    Hao S; Hong CS; Feng J; Yang C; Chittiboina P; Zhang J; Zhuang Z
    J Neurosurg; 2016 Jun; 124(6):1562-7. PubMed ID: 26473790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enchondromatosis and Growth Plate Development.
    Zhang H; Alman BA
    Curr Osteoporos Rep; 2021 Feb; 19(1):40-49. PubMed ID: 33306166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
    Rakheja D; Fuda F; Vandergriff T; Boriack R; Medeiros BC; Frankel AE; Chen W
    Hum Pathol; 2015 Feb; 46(2):322-6. PubMed ID: 25481493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.